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http://dx.doi.org/10.1016/j.kjms.201Abstract The safety of quantum dots (QDs) 705 was evaluated in this study. Mice were
treated with QD705 (intravenous) at a single dose of (40 pmol) for 4, 12, 16, and 24 weeks.
Effects of QD705 on kidneys were examined. While there was a lack of histopathology, reduc-
tion in renal functions was detected at 16 weeks. Electron microscopic examination revealed
alterations in proximal convoluted tubule (PCT) cell mitochondria at even much earlier time,
including disorientation and reduction of mitochondrial number (early change), mitochondrial
swelling, and later compensatory mitochondrial hypertrophy (enlargement mitochondria: giant
mitochondria with hyperplastic inner cristae) as well as mitochondrial hyperplasia (increase in
mitochondrial biogenesis and numbers) were observed. Such changes probably represent
compensatory attempts of the mitochondria for functional loss or reduction of mitochondria
in QD705 treated animals. Moreover, degeneration of mitochondria (myelin-figure and cyto-
plasmic membranous body formation) and degradation of cytoplasmic materials (isolated cyto-
plasmic pockets of degenerated materials and focal cytoplasmic degradation) also occurred in
later time points (16e24 weeks). Such mitochondrial changes were not identical with those
induced by pure cadmium. Taken together, we suggest that mitochondria appeared to be
the target of QD705 toxicity and specific mitochondrial markers may be useful parameters
for toxicity assessments of QDs or other metal-based nanomaterials.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.ad, Zhunan, Miaoli County 350, Taiwan.
(P.-P. Lin).
vier Taiwan LLC. All rights reserved.
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S54 C.-H. Lin et al.Introduction Animal treatmentsQuantum dots (QDs) 705 is a cadmium/selenium/tellurium-
based QDs with unique fluorescent properties and was
found to be highly suitable for biomedical applications [1].
Because the core of QD705 consists of toxic metals,
cadmium and tellurium, the “safety” of QD705 for
biomedical utilization has remained a serious concern.
While there is no lack of investigation on the safety or
toxicity of QD705 [2e5], there was a concern that many of
these studies were not conducted by toxicologists or eval-
uated by qualified pathologists, and, thus, the conclusions
in some of these studies were deemed questionable [2].
Furthermore, most pathology or cytotoxicity assessments in
the past were dependent on relatively nonsensitive and
nonspecific histopathologic methods and these traditional
approaches were unlikely to detect subtle changes
(subcellular changes) in cells and tissues. More sensitive or
specific methods are therefore needed to provide more
reliable and accountable assessments for the evaluation of
QD705 toxicity.
A review further pointed out that most negative reports
in the past were generated from short termed in vivo
studies [2]. Indeed, our previous studies have demonstrated
that QDs have an extremely long retention time in the
biologic system [6,7]. It also has preferential distributions
in certain organs and tissues in vivo [8,9]. Therefore, overly
early evaluations or searching for pathologic changes in
wrongly selected tissues may yield misleading results and
conclusions. Our recent studies further demonstrated that
kidney was the target organ for QD705 accumulation and
deposition [6]. Based on these findings, kidney should be
considered as one of the “target organs” for potential QD-
toxicity.
Changes in mitochondria by QDs have been suggested by
several investigators in the past [10e12]. As early as 2005,
Lovric and colleagues [13] had already projected that mito-
chondria were “early targets of QD-stress and are severely
damaged by QDs.” However, actual demonstrations on
mitochondrial alterations and damages by QDs are still lack-
ing. In our present study, we intend to examine subcellular,
especially mitochondrial, changes in QD705-treated renal
tubular epithelial cells by electron microscopy. Information
obtained in this study, we believe, not only provide the
needed evidence on mitochondrial changes induced by QDs,
but will also provide an important model for future assess-
ments on the safety or toxicity of QDs.Materials and methods
Quantum dots used in the study
The nanoparticles, QD705, used in our experiments were
purchased from Invitrogen, Inc. (Hayward, CA, USA) as
Qtracker 705 nontargeted quantum dots. This QD705 con-
sisted of a Cd/Se/Te core covered with a thin ZnS shell and
methoxy-polyethylene glycol (PEG)-5000 coating. QD705
analyses in our laboratory revealed that our QD705 consisted
of 56.16 8.54%Cd, 5.80 3.60% Se, and0.92 0.20%Teand
had a diameter of approximately 20 nm.Six-week-old male Imprinting Control Region (ICR) mice
(BioLASCO, Taipei, Taiwan) were used in our study. All
animals were acclimated for 2 weeks in the animal
facilities at the National Health Research Institutes
(NHRI) before treatment. All animal treatments and
experimental protocol for this study were subjected to
prior review and approval of the Animal Care Committee
at NHRI before usage. Furthermore, animal handling was
made in accordance to standard animal husbandry prac-
tices and regulations. Animals were also treated
humanely with regard for alleviation of suffering
throughout the study. All mice in this study were housed
under a 12-hour light/dark cycle and at 23  1C, 39e43%
relative humidity. Water and food were available ad
libitum. Ten mice were randomly selected for per time
point of study. Each mouse was intravenously injected
(via tail vein), with 40 pmol of QD705 in saline (20 ml of
2 mM solution). The injection volume was 100 ml per
mouse. (The intravenous route of exposure was used to
mimic potential human exposures for medical imaging
applications.) Sacrifices (under pentobarbital anesthesia)
were performed at 4, 12, 16 and 24 weeks after dosing.
Since kidneys were found to be the “major organ” for
QD705 accumulations in mice, these organs were used in
our present evaluations. Kidneys were carefully
removed, weighed, and prepared for studies in this
investigation.
Histopathology and tissue preparations
Tissue specimens from the kidneys were fixed in buffered
10% formalin for 48 hours prior to tissue processing (dehy-
dration and paraffin embedding). Sections were cut at 3 mm
thick with rotary microtome. Hematoxylin and eosin (H&E)
were used for general histology staining in accordance to
standard H&E staining procedures.
Clinical biochemistry analysis
The concentrations of blood urea nitrogen (BUN) and
creatinine in serum were determined for assessing renal
functions. Blood was collected from heart after anes-
thetization. Blood samples were centrifuged at 1500  g
for 15 minutes to remove the clot. A total of 400 ml serum
was used to determine BUN and creatinine concentra-
tions with VITROS 350 Chemistry System (Ortho Clinical
Diagnostics, Johnson & Johnson, Kowloon, Hong Kong) at
the Veterinary Hospital, National Taiwan University,
Taipei, Taiwan.
Electron microscopy findings
Renal cortex from the kidney was sampled, diced into 1
cubic meter sizes, and fixed with 1% glutadehyde for 48
hours. All tissue samples were further fixed and stained
with 0.5% osmium tetroxide over night before embedding in
epoxy resin. All sections were cut at 1-mm thick and
examined with a transmission electron microscope (H-7650;
Hitachi, Tokyo, Japan).
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Comparison of data between groups was performed by
Student t test. Differences between data were considered
significant at p < 0.05.
Results
Histopathologic examinations
Tissue sections were stained with standard H&E stain and
were examined with a research light microscope. No
specific or significant histopathology was detected in the
kidney tissues via H&E staining at any time point (4, 12, 16,
and 24 weeks) of the study.
Measurements for renal function
Renal functions were assessed by measuring BUN and
creatinine concentrations in serum at 12 and 16 weeks.
Both concentrations were not elevated at 12 weeks and
then significantly elevated at 16 weeks following injection
of 40 pmol of QD705 (Table 1). These results showed that
renal function, determined by clinical biochemistry
methods, was reduced at 16 weeks after 40 pmol of QD705
injection.
Electron microscopy findings
Electron microscopic appearance of a normal proximal
convoluted tubule (PCT) epithelial cell is illustrated in
Fig. 1A. Note the consistency in sizes and shape of the
mitochondria that are aligned within the confines of the
basal infoldings in the PCT epithelial cell in a well-oriented
fashion. The normal mitochondria also have a uniform
matrical density with well-developed inner cristae (Figs. 1A
and 2A). With electron microscopy, a series of morphologic
alterations and pathologic changes could be identified in the
renal PCT epithelial cells from QD705-treated mice. At 4
weeks after 40 pmol of QD705 injection, many PCTepithelial
cells were found to have lost their basal infoldings. Mito-
chondria of various sizes were also found to be scattered in
the cell cytoplasm without alignment and orientation
(Fig. 1B). Closer examinations revealed that many mito-
chondria were edematous and swollen (enlarged). These
abnormal swollen mitochondria acquired rounded configu-
ration and with “watery” matrices. With such edematous
condition of the mitochondria, many inner cristae of the
mitochondria became shortened or broken (Fig. 2B). In
addition, another type of mitochondrial enlargement wasTable 1 Effects of QD705 on renal function.
Time (wk) Treatment BUN (mg/dL) Creatinine (mg/dL)
12 Control 21.42  4.70 0.26  0.05
QD705 24.08  2.61 0.28  0.07
16 Control 22.33  2.58 0.27  0.05
QD705 27.83  3.82* 0.32  0.04*
*p < 0.05, as compared with control group.
BUN Z blood urea nitrogen.also observed at this time of exposure (4 weeks). Unlike the
swollen mitochondria, these giant or hypertrophied mito-
chondria could become extremely enormous in size. These
giant mitochondria maintained a floccular matrical density
and prominent inner cristae (Fig. 2C). Such abnormal giant
mitochondria could still be found at 24 weeks after QD705
exposure (Fig. 3). At this late time, some of these hyper-
trophied giant mitochondria also developed hyperplastic
cristae (Fig. 3A) give rise to long and complex cristae
networks resembling fingerprint patterns within these
mitochondria (Fig. 3B).
By contrast to “enlargements” of mitochondria (either
swollen or hypertrophied), some PCT epithelial cells dis-
played large numbers of mitochondria within extremely
small sizes (micro-mitochondria). A comparison of normal,
giant, and micro-mitochondria is demonstrated in Fig. 4A.
Careful examinations revealed thatmanymitochondriawere
engaged in budding activity (mitochondrial division) leading
to many micro-mitochondria in these cells (Fig. 4B). These
variants in mitochondrial sizes (giant and micro-
mitochondria) could be observed in PCT cells throughout
our study period (4e24 weeks). At late period (around 16e24
weeks), some PCT epithelial cells displayed cytoplasm with
extremely high density of mitochondria (Fig. 5A). Such
significant increase in mitochondrial number was probably
the result of the increased mitochondrial budding activity in
these cells at an earlier time (4e16 weeks).
While some PCT epithelial cells showed increases in
mitochondrial size (mitochondrial hypertrophy) and
number, many PCT cells actually also displayed a drastic
reduction in mitochondrial numbers. This finding of reduc-
tion in mitochondrial number in the PCT cells was especially
prominent at an earlier time period (4e12 weeks). This is
shown in Fig. 5B. Therefore, we suggest that increases in
mitochondrial size and numbers probably represent
morphologic alterations of the mitochondria as a compen-
sational attempt for the reductions in mitochondrial
number and function induced by QD705. A comparative
illustration of the great variants in mitochondrial
morphology (size, shape, numbers, and orientations) in the
kidney of QD705 -treated animals compared with the
normal controls; this is demonstrated in Fig. 6.
Aside from such compensatory modifications and alter-
ations of mitochondria, degenerations of mitochondria in
the PCT cells of QD705-treated animals were also observed.
Mitochondrial breakdowns to form membranous bodies
(myelin figures) could be detected as early as 4 weeks
(Fig. 7A and B) leading to many multiple concentric
membranous bodies (CMBs) in many PCT cells (Fig. 7C). By
12 weeks, isolated “cytoplasmic pockets” (CPs) containing
degenerating cytoplasmic materials, including mitochon-
dria, could be found in many PCT cells (Fig. 8A). At 16e24
weeks, multiple and dense focal cytoplasmic degenerative
(FCD) areas could be detected in many PCT epithelial cells
(Fig. 8B). Various time-related mitochondrial alterations
are represented and summarized in Fig. 9.Discussion
Although QDs have tremendous potential for various
applications, their biosafety is still very controversial.
Figure 1. (A) Normal renal proximal convoluted tubule (PCT) epithelial cells, mouse, normal. Note the uniformity in sizes of the
mitochondria and the well orientation (alignment) of the mitochondria within the confines of the basal infoldings. (20,000);
(B) PCT epithelial cell, mouse, QD705-treated (4 weeks). Note the great variations in mitochondrial size, absence of basal
infoldings, and total disorientation of the mitochondria within the cell cytoplasm (10,000).
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nanomaterial [2e5]. A recent study coupling with histo-
pathology and blood chemistry (organ functional markers)
claimed that QD705 was totally “safe” with 80 days’
toxicity evaluation [3]. In our present study, alterations in
renal functions were not observed until at 16 weeks (112
days) in animals treated with QD705 indicating that QD705
may have a slow or delayed toxicity and may not be
noticeable at early time periods. Furthermore, our own
histopathology studies via H&E staining and light micro-
scopic examination, either in the present or past [9], also
failed to detect significant histopathologic damages in the
kidneys of QD705-treated animals even at late periods of
the studies. These failures to detect reduction in renal
functions at earlier time points and the absence of renal
histopathology raised the question: Are general histopa-
thology (H&E staining) and blood chemistry sensitive and
specific enough to detect subtle and specific injuries in
cells and tissues induced by QDs or other nanomaterials?
The answer is obviously no. These methods are very
general and nonspecific techniques in detecting more
overt cell and tissue damages with significant cell degen-
erations and deaths (necrosis or apoptosis). Indeed, bymeans of more specific MitoTracker Red staining method,
aggregations of swollen or enlarged mitochondria in
QD705-treated cells have been reported before [13,14],
suggesting that QDs might induce more subcellular
changes without overt cell degenerations or death. These
findings further suggested a functional loss or reduction in
the mitochondrial function by QDs [13,15]. These investi-
gators further indicated that such changes occurred prior
to cell deaths (apoptosis) suggesting that mitochondria
may actually be early targets of QDs toxicity. In our
present study, we have observed a reduction in the
number of mitochondria in the PCT cells at earlier time
points of QD exposure (4e12 weeks). Despite there was
demonstration on reduction of mitochondrial enzymes and
functions upon QD exposures [13,15], actual mitochondrial
changes and damages during the periods of QD705 injec-
tion still need to be demonstrated and verified. Since
mitochondria are subcellular organelles that are difficult
to be visualized at light microscopic level, mitochondrial
alterations and damages must be demonstrated with
electron microscopy. In our present study, as early as 4
weeks after exposure to QD705, swelling of mitochondria
in the renal PCT epithelial cells could be readily
Figure 2. (A) Normal mitochondria from mouse renal PCT epithelial cell. Note the intactness of the inner cristae within the
mitochondrial matrix of uniform density (30,000); (B) swollen mitochondria from PCT epithelial cells, mouse, QD705-treated (4
weeks). Note the roundness and enlargement of the mitochondrial shape and size. Many of these edematous mitochondria had
matrices with watery appearance and broken inner cristae (20,000); (C) giant or mega mitochondria from a PCT epithelial cell,
mice, QD705-treated (4 weeks). Note the tremendously enlarged size of the mitochondria was also observed. Despite the
enlargement, there was maintenance of the mitochondrial matrix density as well as intactness of the inner cristae (40,000).
Figure 3. (A) APCT epithelial cell from a mouse treated with QD705 (24 weeks) showing many hypertrophied mitochondria (giant
or mega mitochondria) with long and distinct inner cristae (15,000); (B) mitochondria in a PCT epithelial cell, mouse, QD705-
treated (24 weeks). Some of the hypertrophied mitochondria also developed highly hyperplastic inner cristae. These long and
complex cristae networks of inner cristae give rise to an appearance resembling finger print pattern (20,000).
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Figure 4. (A) PCT epithelial cell, QD705-treated (4 weeks). Asides from development of giant or mega mitochondria (Mg), many
extremely small mitochondria (micro-mitochondria) (indicated by arrows) as compared with those of normal size (N) were also
found (10,000); (B) budding mitochondria in a PCT epithelial cell, QD705-treated (4 weeks). Between 4e16 weeks, mitochondrial
budding (division) was frequently found in PCT epithelial cells. Such rapid and increased budding of mitochondria (biogenesis of
mitochondria) may be responsible to the many small (micro-) mitochondria seen during this time period (50,000).
S58 C.-H. Lin et al.demonstrated by electron microscopy. Alternatively, this
type of mitochondrial change represents only non-specific
mitochondrial injury, which can be induced by many renal
toxicants, including cadmium chloride (CdCl2) [16e18].
Since cadmium is a major component of QD705, the
influence by cadmium released from degraded QD705 [6]
cannot be totally excluded.
While the mitochondria in normal PCT are usually fairly
consistent in size and are always well oriented (posi-
tioned) within the confines of the basal infoldings of the
PCT cells, many PCT epithelial cells in QD705-treated
animals showed an absence of basal infoldings and
totally disoriented mitochondria. This ultrastructural
finding probably represents the disruption of “tubular
mitochondrial network” described by Lovric and
colleagues [13] via light microscopic examination of QD-
treated Michigan Cancer Foundation (MCF)-7 cells.
However, with electron microscopy, a great variation in
mitochondrial sizes could also be demonstrated in this
study. Most notably, many mitochondria became
extremely large (giant-mitochondria). Unlike swollen
mitochondria, these giant mitochondria maintained good
matrical density and intact inner cristae. Abnormal
proliferation of the inner membrane (cristae), giving rise
to “finger-print” configuration of the enlarged mitochon-
dria was also demonstrated at later time of the study
(16e24 weeks). We suggest that the enlargement ofmitochondria (hypertrophied mitochondria) with hyper-
plastic cristae represents a compensatory response to the
reduction of mitochondrial numbers or mitochondrial
functions (loss of cytochrome C oxidase activity) reported
by other investigators [13,15]. Similar compensatory
effects on defective of mitochondria have been observed
in other health conditions such as in heart muscles of
certain cardiomyopathy patients [19] and in skeletal
muscles of patients with congenital muscular dystrophy
[20]. The changes in mitochondria that we have observed
in this study are striking and exciting. Because except in
some chronic human diseases [19e23], no ordinary
chemical is known to induce such dynamic structural
changes in mitochondria. Electron microscopy is a much
more sensitive tool to detect “pathology” than traditional
histopathology. To our knowledge, we are the first to
demonstrate actual structural and pathologic alterations
and degeneration of mitochondria induced by QD705 and
eluted to its health risk.
While the formation of giant mitochondria is an attempt
of "compensation" for reduced mitochondrial number or
function, we believe that “decompensation” of these
enlarged mitochondria would eventually occur leading to
the degenerative CMB found in the PCT epithelial cells. At
later time point (24 weeks), multiple areas of CP of
degenerations and FCD were formed as cytoplasmic
attempts to confine and degrade the degenerative cellular
Figure 5. (A) PCT epithelial cells, QD705-treated (24 weeks). These PCT cells showed very high density of mitochondria pop-
ulation in their cytoplasm (6000). This hyperplastic (increase in number) condition of mitochondria was probably resulted from an
increased biogenesis (budding) of mitochondria; (B) PCT epithelial cell, QD705-treated (12 weeks). At earlier time periods (4e12
weeks), many PCT epithelial cells actually showed a reduction in mitochondrial number as compared to similar cells from control
animals (10,000).
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mitochondrial changes and cytoplasmic degradation, the
affected PCT cells were still “alive.” This may explain that
cell death or “remarkable histopathology” was not readily
observed at light microscopic level, especially via non-
specific H&E staining.
Aside from “enlargement” in size, mitochondria can
also compensate their functional loss by increase in
number. This type of "abnormal mitochondrial prolifera-
tion" has been observed and described in certain drug
treatments or under highly stressful conditions [22,23].
Abnormal mitochondrial biogenesis (proliferation) is one
of the prominent histological hallmarks in muscle from
patients with mitochondrial encephalomyopathy [21]. This
phenomenon is known as compensatory mitochondrial
biogenesis which takes place as an attempt to counteract
energy deficits [23]. Indeed, careful examination of the
QD-treated kidneys also revealed an increase in extremely
small mitochondria (micro-mitochondria) in many PCT
cells. Frequent mitochondrial budding (division), which is
usually seldom captured in normal cells, was also evident.
This active mitochondrial budding denoted activemitochondrial proliferation (biogenesis), which was
observed at earlier time point of the study (4e12 weeks).
Overcompensation may have occurred in some cells.
We believe that the high density or population of mito-
chondria in some PCT cells at later study time points
represented such overcompensation.
In our previous study, we have demonstrated release of
free cadmium from QD705 in the kidney tissues [6]. Because
cadmium is highly toxic, many assumptions were made that
suggested the toxicity of cadmium-based QDs was probably
induced by the cadmium released [1,2,24,25]. If it is so,
then the mitochondrial changes observed in our present
study should be identical to those reported in cadmium
toxicity [16e18]. However, aside from mitochondrial
swelling, most of the mitochondrial alterations observed in
our study, such as compensatory changes in size and
numbers of mitochondria and decompensation of giant
mitochondria to form CMBs and FCDs, were not commonly
seen or described in cadmium nephropathy [16e18,26,27].
Furthermore, renal tubular necrosis and glomerular
changes, which are frequently observed in cadmium
nephropathy [27,28], are not found in the QD-treated
Figure 6. QD705 (12 weeks). A comparative illustration of
PCT epithelial cells demonstrating great variances in mito-
chondrial size, shape, and number. The cell in upper left
represents appearance of a normal PCT with normal mito-
chondria. Note the uniformity of size and shape as well as
numbers and one-directional orientation (alignment) of the
mitochondria. The other two cells (upper right and lower half)
displayed tremendous reduction in mitochondria number and
great variances in size, shape, and orientations of the mito-
chondria (6000).
S60 C.-H. Lin et al.animals. Thus, the QD-toxicity observed in this study should
not be equated with those of pure cadmium toxicity.
Furthermore, tellurium, another metallic component in the
QD705 core, is also known to be a renal toxin [29e31].Figure 7. Mitochondrial degeneration in PCT cells, mouse, QD7
mitochondria (30,000); (B) 12 weeks, myelin formation in cyt
membranous degeneration of mitochondria (20,000); (C) 24 wee
could be demonstrated. These large concentric membranous bodieWe cannot exclude the possibility that the specific mito-
chondrial changes that we have observed may represent
combined effects of cadmium and tellurium or other
factors.
Our previous studies have identified the kidneys to be
the target organ for QD705 accumulation [6,8,9]. Now we
further demonstrated that mitochondria in PCT cells are
specific targets for QD705 toxicity. It should be pointed out
that mitochondria are actually favorite targets for toxicity
of many metals, such as Hg, Cd, Cu, Fe, As, Al, and Pb
[16e18,32e36], which are known to cause mitochondrial
dysfunction, oxidative stress, and degeneration. Further-
more, mitochondrial permeability transition, a pore-
mediated impairment of mitochondrial function, has
been indicated to participate in cytotoxic action of metal
ions [37]. Thus, we propose that mitochondrial markers
should be developed as specific parameters for sensitive
toxicity evaluation, not just for QDs, but also for many
other metal-based nanomaterials. It must be pointed out
that cell death alone, either in vitro or in vivo, is not
a good or sensitive parameter to define toxicity. The most
worrisome toxic endpoint, in fact, should be subtle cell
alterations (including cancer) without cell death
(apoptosis). Thus, traditional histopathology or other
general cytotoxicity methods, which may be useful in
detecting overt cell deaths or tissue damages, are too
insensitive and nonspecific for the detection of early and
subtle cellular changes induced by some nanomaterials.
Nanotechnology is one of the most revolutionary devel-
opments in the 21st century, influencing almost every
aspect of human life. Sensitive and innovative approaches
for biosafety assessment are needed to meet the new
challenges of the 21st century. Hopefully our study will
inspire developments of new and specific parameters,
such as mitochondrial markers, for future biosafety eval-
uations in the future.05-treated. (A) 4 weeks, break down of inner membranes of
oplasm near mitochondrial population. These may represent
ks, large concentric membranous bodies in the cell cytoplasm
s may represent aggregates of myelin bodies in cells (15,000).
Figure 8. Cytoplasmic degradation in PCT epithelial cells, mouse, QD705. At late time period (12e24 weeks), areas of cyto-
plasmic degradation in some PCT cells were also observed. (A) 12 weeks, isolated cytoplasmic pockets with confined degenerative
cytoplasmic materials, including mitochondria, were demonstrated (10,000); (B) 24 weeks, many focal cytoplasmic degeneration
areas consisted of degraded proteins and membranous materials could be found in some PCT cells from animals treated with
QD705. These focal cytoplasmic degradation areas represent generalized cytoplasmic degeneration independent or secondary to
mitochondrial degeneration (6000).
Figure 9. Diagrammatic summary on time-correlated mitochondrial alterations in PCT epithelial cells from mouse treated with
QD705. Alteration of mitochondrial structure, numbers and degeneration by QD705.
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